Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically proven progressive advanced solid tumor that is not
amenable to standard therapy (i.e., resistant to standard therapy or for which no
standard therapy exists)

- No clinically symptomatic CNS involvement

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- ECOG 0-2

Life expectancy:

- At least 3 months

Hematopoietic:

- WBC at least 3,000/mm^3

- Neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

Hepatic:

- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- AST and ALT less than 2 times ULN (5 times ULN if liver metastases present)

- Alkaline phosphatase less than 2 times ULN (5 times ULN if liver metastases present)

Renal:

- Creatinine less than 1.4 mg/dL

Cardiovascular:

- No ECG abnormalities of clinical relevance

Other:

- No severe or unstable systemic disease or infection

- No circumstances (e.g., alcoholism or substance abuse) that would preclude study

- HIV negative

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- At least 4 weeks since prior immunostimulating substances (e.g., biologic response
modifiers or colony-stimulating factors)

- No concurrent immunostimulating substances (e.g., biologic response modifiers or
colony-stimulating factors (except in life-threatening situations))

Chemotherapy:

- At least 4 weeks since prior chemotherapy

Endocrine therapy:

- At least 4 weeks since prior systemic steroids

- At least 4 weeks since prior hormonal therapy

- No concurrent systemic steroids

Radiotherapy:

- At least 4 weeks since prior radiotherapy

- No concurrent radiotherapy

Surgery:

- Not specified

Other:

- No prior mistletoe preparations

- At least 4 weeks since prior investigational treatment

- No other concurrent anticancer agents

- No other concurrent investigational therapy